Meaxin (Imatinib)

Imatinib acts on abnormal tyrosine kinase signaling pathways, providing targeted therapy for specific cancers.

• Chronic myeloid leukemia (CML): achieves disease control by reducing leukemic cell proliferation.
• Gastrointestinal stromal tumor (GIST): achieves tumor shrinkage and disease stabilization.

• Imatinib selectively inhibits the BCR‑ABL fusion protein tyrosine kinase, as well as c‑KIT and PDGFR kinases. By binding to the ATP‑binding site of these enzymes, it blocks downstream phosphorylation cascades that drive uncontrolled cell growth and survival, leading to apoptosis of malignant cells. The inhibition is competitive and reversible, allowing precise modulation of signaling pathways involved in hematopoietic and gastrointestinal stromal tumor pathogenesis.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: swelling of extremities, especially ankles.
• Muscle cramps: occasional skeletal muscle discomfort.
• Fatigue: general tiredness and reduced energy.
• Diarrhea: loose stools, often transient.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe neutropenia: marked reduction in white blood cells.
• Cardiac failure: signs of reduced heart function.
• Pulmonary hypertension: increased pressure in lung arteries.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hemorrhage: abnormal bleeding events.

When prescribing Imatinib, clinicians should observe several safety measures to minimize risks.

• Monitor liver function: perform baseline and periodic hepatic enzyme tests.
• Assess blood counts: regular CBC to detect neutropenia or anemia.
• Evaluate cardiac status: check for pre‑existing heart disease and monitor for signs of heart failure.
• Caution in renal impairment: adjust dosing and monitor renal function as needed.
• Avoid in hypersensitivity: discontinue if allergic reactions occur.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Imatinib interacts with several medicines; awareness of these interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower imatinib exposure.
• Antacids containing aluminum or magnesium: can reduce oral absorption of imatinib.

Moderate Interactions (Monitor Closely)

• Warfarin: may increase anticoagulant effect, requiring INR monitoring.
• Diuretics (e.g., furosemide): may enhance risk of fluid retention.
• Other CYP3A4 substrates (e.g., midazolam): may have altered concentrations.
• QT‑prolonging agents: combined use may increase risk of cardiac arrhythmias.